Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 9/20 | 0.90 |
| ▸ | ACHE | P22303 | 9/20 | 0.90 |
| ▸ | EP300 | Q09472 | 4/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.90 |
| ▸ | LMNA | P02545 | 2/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.90 |
| ▸ | MAPT | P10636 | 2/20 | 0.90 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.90 |
| ▸ | DRD2 | P14416 | 2/20 | 0.90 |
| ▸ | TSHR | P16473 | 2/20 | 0.90 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.90 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.90 |
| ▸ | RXRA | P19793 | 2/20 | 0.90 |
| ▸ | DRD1 | P21728 | 2/20 | 0.90 |
| ▸ | HTR2B | P41595 | 2/20 | 0.90 |
| ▸ | HTT | P42858 | 2/20 | 0.90 |
| ▸ | RAD52 | P43351 | 2/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Berberine SCHEMBL29569974 | 0.99 | BCHE (0.89) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL15669190 | 0.95 | ACHE (1.00) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL30153843 | 0.95 | ACHE (1.00) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL25632 | 0.95 | ACHE (1.00) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL29354144 | 0.95 | ACHE (1.00) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL16781367 | 0.94 | ACHE (0.90) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL4894622 | 0.94 | BCHE (0.98) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL153906 | 0.94 | ACHE (1.00) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL21462194 | 0.94 | ACHE (0.98) | BCHEACHEEP300ALDH1A1LMNA | |
| Berberine SCHEMBL10709599 | 0.94 | ACHE (0.98) | BCHEACHEEP300ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567459-A | Berberine organic acid salt and preparation method and application thereof | 郑州大学 | 2024-02-20 | — | — | CN | claimed |
| CN-111205285-B | Purification method and crystal form of berberine or berberine salt | 江西富祥药业股份有限公司 | 2021-09-17 | — | — | CN | claimed |
| CN-111205285-A | Purification method and crystal form of berberine or berberine salt | 江西富祥药业股份有限公司 | 2020-05-29 | — | — | CN | claimed |
| US-20130071474-A1 | COMBINATIONS OF BERBERINE, ARTEMISININ, Loperamide AND THEIR DERIVATIVES TO TREAT MALARIA, DIARRHEA, TRAVELERS' DIARRHEA, DYSENTERY, DENGUE FEVER, PARASITES, CHOLERA AND VIRUSES | Spencer, James (US) | 2013-03-21 | — | — | US | claimed |
| WO-2012108892-A1 | COMBINATIONS OF BERBERINE, ARTEMISININ, LOPERAMIDE AND THEIR DERIVATIVES TO TREAT MALARIA, DIARRHEA, TRAVELERS' DIARRHEA, DYSENTERY, DENGUE FEVER, PARASITES, CHOLERA AND VIRUSES | SEUBERT KIRK (US) | 2012-08-16 | — | — | WO | claimed |
| US-6280768-B1 | ADMINISTERING BERBERINE ALKALOID, AND CONTINUING ADMINISTRATION FOR SUFFICIENT TIME TO ALLEVIATE CHRONIC DIARRHEA INDUCED BY PROTOZOA SELECTED FROM GROUP CONSISTING PROTOZOA SELECTED FROM MICROSPORRIDIA AND CRYPTOSPORDIA SPP. | PRM PHARMACEUTICALS, INC. | 2001-08-28 | — | — | US | claimed |
| WO-1998000018-A1 | BERBERINE ALKALOIDS AS A TREATMENT FOR CHRONIC, PROTOZOALLY-INDUCED DIARRHEA | PRM PHARMACEUTICALS, INC. (US) | 1998-01-08 | — | — | WO | claimed |
| CN-117567459-A | Berberine organic acid salt and preparation method and application thereof | 郑州大学 | 2024-02-20 | — | — | CN | disclosed |
| CN-117567459-A | Berberine organic acid salt and preparation method and application thereof | 郑州大学 | 2024-02-20 | — | — | CN | disclosed |
| CN-115887552-A | Chinese medicinal Shuanghuang antibacterial and anti-inflammatory spray liquid and preparation method thereof | 十堰市太和医院（湖北医药学院附属医院） | 2023-04-04 | — | — | CN | disclosed |
| US-20220185807-A1 | CRYSTALLINE BERBERINE ASCORBATE SALT, METHODS OF PREPARATION AND APPLICATIONS THEREOF | Beiture LLC (US) | 2022-06-16 | — | — | US | disclosed |
| US-11345697-B1 | Crystalline berberine ascorbate salt, methods of preparation and applications thereof | Beiture LLC (US) | 2022-05-31 | — | — | US | disclosed |
| CN-111205285-B | Purification method and crystal form of berberine or berberine salt | 江西富祥药业股份有限公司 | 2021-09-17 | — | — | CN | disclosed |
| US-6280768-B1 | ADMINISTERING BERBERINE ALKALOID, AND CONTINUING ADMINISTRATION FOR SUFFICIENT TIME TO ALLEVIATE CHRONIC DIARRHEA INDUCED BY PROTOZOA SELECTED FROM GROUP CONSISTING PROTOZOA SELECTED FROM MICROSPORRIDIA AND CRYPTOSPORDIA SPP. | PRM PHARMACEUTICALS, INC. | 2001-08-28 | — | — | US | disclosed |
| WO-1998000018-A1 | BERBERINE ALKALOIDS AS A TREATMENT FOR CHRONIC, PROTOZOALLY-INDUCED DIARRHEA | PRM PHARMACEUTICALS, INC. (US) | 1998-01-08 | — | — | WO | disclosed |
| US-4980344-A | Compositions for improving circulatory performance | MAROKO, ANDREW | 1990-12-25 | — | — | US | disclosed |
| EP-0184118-B1 | 13-PROPYLBERBERINE SALTS | SS PHARMACEUTICAL CO., LTD. (JP) | 1988-08-17 | — | — | EP | disclosed |
| US-4761477-A | ANTISECRETORY AGENTS | SS PHARMACEUTICAL CO., LTD. (JP) | 1988-08-02 | — | — | US | disclosed |
| US-4749708-A | Composition for improving circulatory performance | MAROKO, ANDREW | 1988-06-07 | — | — | US | disclosed |
| EP-0184118-A1 | 13-propylberberine salts | SS PHARMACEUTICAL CO., LTD. (JP) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185807-A1 | CRYSTALLINE BERBERINE ASCORBATE SALT, METHODS OF PREPARATION AND APPLICATIONS THEREOF | CBR1, BBC3, BCL6B | BCHE 31/4885ACHE 1343/4885EP300 3701/4885 |
| US-11345697-B1 | Crystalline berberine ascorbate salt, methods of preparation and applications thereof | CBR1, BBC3, BCL6B | BCHE 31/4885ACHE 1343/4885EP300 3701/4885 |
| US-20130071474-A1 | COMBINATIONS OF BERBERINE, ARTEMISININ, Loperamide AND THEIR DERIVATIVES TO TREAT MALARIA, DIARRHEA, TRAVELERS' DIARRHEA, DYSENTERY, DENGUE FEVER, PARASITES, CHOLERA AND VIRUSES | ABCB11, ABCB1, VIP | BCHE 153/4885ACHE 35/4885EP300 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.